Results 291 to 300 of about 181,460 (361)

Can atogepant be a preventive treatment for cluster headache?—Insights from a case series

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Cluster headache (CH) is a disabling primary headache disorder with limited therapeutic options. Calcitonin gene‐related peptide (CGRP) is known to be involved in CH pathophysiology; however, except for galcanezumab (300 mg) in episodic CH, anti‐CGRP monoclonal antibodies did not reduce CH attacks in randomized clinical trials. Atogepant is an
Catarina Serrão   +3 more
wiley   +1 more source

Perceived disabling physical pain and suicidal ideation in aging people living with HIV cured of hepatitis C: A multi‐center survey in France (ANRS CO13 HEPAVIH)

open access: yesHIV Medicine, EarlyView.
Abstract Introduction Suicidal ideation (SI) is highly prevalent among people living with HIV (PWH) and those with chronic hepatitis C virus (HCV) infection. Individuals with long‐term HIV–HCV co‐infection face specific health challenges, including heightened physical pain.
Tangui Barré   +402 more
wiley   +1 more source

Recognising the Imminence of Suicide Risk—Reframing Positive Obligations Under the European Convention on Human Rights

open access: yesThe Howard Journal of Crime and Justice, EarlyView.
ABSTRACT This article reframes the concept of imminence of suicide risk of mentally ill offenders under Article 2 of the European Convention on Human Rights, which enshrines the right to life. The proposal is based on Article 2 domestic violence jurisprudence which has built its knowledge of lethal risk by reference to relevant expertise.
Sabina Garahan
wiley   +1 more source

Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Background The United States Food and Drug Administration (FDA) approved oral finasteride for androgenetic alopecia. In 2022, approximately 2.6 million U.S. men used it for hair loss and prostate conditions. Post‐finasteride syndrome (PFS), proposed in 2012, involves persistent sexual and neuropsychiatric adverse events (AEs) after cessation ...
Aditya K. Gupta   +3 more
wiley   +1 more source

Association between sarcopenia and suicidal ideation in a nationwide population-based study. [PDF]

open access: yesSci Rep
Song E   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy